Navigation Links
Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
Date:1/27/2011

e obtained at the SEC's website at www.sec.gov or from Roth Capital Partners, LLC by e-mail to rothecm@roth.com or by mail to 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, Pennsylvania 19422.

About Inovio Pharmaceuticals, Inc.Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... Extensiv hydrolysierte Milch ... Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ist die ... Kleinkindern. Der bisher übliche Umgang mit dieser ... bzw. deren stillenden Mütter Milchproteine zu vermeiden. ... einer beträchtlichen Anzahl von Kindern der Aufbau ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... 2011 Aethlon Medical, Inc. (OTCBB: ... to address infectious disease and cancer, announces that ... a company overview, discuss recent developments and review ... & Medical Technologies Virtual Conference.   ...
... June 7, 2011 CMR Institute , the leading ... announces the addition of two new e-modules to help representatives ... (ACA): The Affordable Care ... Accountable Care Organizations and Future Healthcare Delivery ...
Cached Medicine Technology:Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 2Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 3CMR Institute Adds e-Modules Addressing Healthcare Reform's Impact on Pharmaceutical Industry 2
(Date:10/30/2014)... Chicago, IL (PRWEB) October 30, 2014 Dr. ... launched a new website for his practices; OB GYN ... Chicago, IL . This website contains important information about ... covers as well as downloadable patient forms in English and ... use and the service pages on the website provide Dr. ...
(Date:10/30/2014)... Newport Beach, California (PRWEB) October 30, 2014 ... superfood nutrtion bars are now available through a unique ... an online site designed to empower the everyday athlete. ... the worlds best athletes and created a system to ... really excited to see REV’D® is now available on ...
(Date:10/30/2014)... October 30, 2014 Sound Telecom, a leader ... that will assist people any time they wonder, “Should I ... right answer by leading them through a series of yes ... their initial query. , There are many considerations and scenarios ... use an answering service . This decision infographic serves ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... milk could be bad for your health, a new study ... milk can help strengthen bones and prevent osteoporosis. These benefits ... milk as part of a healthy diet. But this ... not protect men or women from bone fractures, and was ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- A new vaccine ... meningococcal disease was approved by the U.S. Food and ... protect people between the ages of 10 and 25 ... serogroup B bacteria. The bacteria can infect ... spinal cord and brain. It is a leading cause ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... - Month-12 Independent Echocardiographic Data Safety Monitoring ... Safety Profile -, SAN DIEGO, March ... ) announced today that following a planned ... Board (EDSMB) it is,continuing BLOOM (Behavioral modification ...
... now cover Monogram,s Trofile assay, SOUTH SAN ... MGRM ) today announced that the,California Medicaid ... Trofile Assay., Medi-Cal is the state medical ... care and services to individuals,or families on public ...
... supported by the National Institutes of Health (NIH) ... Infectious Diseases (NIAID) has identified chemical compounds that ... parasitic disease that afflicts more than 200 million ... the advance online publication of the journal Nature ...
... can contribute to weight gain, experts say, , , SUNDAY, March ... for some people be as simple as getting some extra ... don,t get enough sleep tend to weigh more -- and ... and ghrelin. , "There is a dynamic balance between ...
... Guidelines Emphasize Importance of Allergy Testing to Control Chronic ... ... 14 Allergy and asthma specialists,from around the country will gather ... (NAEPP) Guidelines for,the Diagnosis and Management of Asthma. These guidelines are ...
... As the state,s leading health,groups working to reduce the ... continued efforts to enforce the Freedom to Breathe,Act by ... by the City of Maplewood are a positive step,toward ... congratulate,their efforts to protect health," said Pat McKone, Director ...
Cached Medicine News:Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 2Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 3Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 4Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 5Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 6Health News:California Medicaid Establishes Coverage for Trofile(TM) 2Health News:California Medicaid Establishes Coverage for Trofile(TM) 3Health News:California Medicaid Establishes Coverage for Trofile(TM) 4Health News:Scientists identify new leads for treating parasitic worm disease 2Health News:Scientists identify new leads for treating parasitic worm disease 3Health News:Starved for Sleep? Watch Your Waistline 2Health News:Starved for Sleep? Watch Your Waistline 3Health News:NIH Asthma Guidelines Will Leave Sufferers Breathing Easier This Spring 2Health News:Leading Health Groups Applaud Continued Efforts to Protect Public Health by Ending So-Called 'Theatrical Productions' in Bars 2
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
... to bring efficiency and quality to routine ... superior technology of fluorescent flow cytometry with ... sampling or batch processing are easily accommodated ... in high volume laboratories. Fluorescent flow ...
... The IsoSleeve™ Source Delivery System incorporates ... design that provides the confidence that each ... prior to implant. Unlike other preloaded needle ... verification of the loading configuration giving you ...
Medicine Products: